Introducing biomarker panel in esophageal, gastric, and colon cancers; a proteomic approach

Gastroenterology and Hepatology from Bed to Bench

Volumn 8, Issue 1, 2015, Pages 6-18

  Zamanian Azodi, Mona ^a   Rezaei Tavirani, Mostafa ^a   Hasanzadeh, Hadi ^b   Rad, Sara Rahmati ^c   Dalilan, Sona ^a   Gilanchi, Samira ^a   Manzour, Haleh ^d  

^a SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b SEMNAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c UNIVERSITY OF TEHRAN   (Iran)

^d Department of Science and Researches Islamic Republic University   (Iran)

Author keywords

Biomarker panel; Colon cancer; Esophagus cancer; Gastric cancer; Proteomics

Indexed keywords

ATG1 PROTEIN; COLON CANCER SPECIFIC ANTIGEN; GASTROKINE 1; MITOGEN ACTIVATED PROTEIN KINASE KINASE KINASE 3; N L116 ANTIGEN; PEPSINOGEN II; PROTEIN KINASE; PSB7 PROTEIN; RETINOBLASTOMA BINDING PROTEIN 2; TUMOR ANTIGEN; TUMOR MARKER; UNCLASSIFIED DRUG;

ABDOMINAL RADIOGRAPHY; BARIUM ENEMA; BARRETT ESOPHAGUS; CANCER CLASSIFICATION; CANCER DIAGNOSIS; CANCER PROGNOSIS; CANCER RESEARCH; CANCER SCREENING; CANCER THERAPY; CARCINOID; COLON ADENOCARCINOMA; COLON CANCER; COLONOSCOPY; COMPUTED TOMOGRAPHIC COLONOGRAPHY; COMPUTER ASSISTED TOMOGRAPHY; DISEASE ASSOCIATION; DOUBLE CONTRAST RADIOGRAPHY; ECHOGRAPHY; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; ESOPHAGOSCOPY; ESOPHAGUS CANCER; FECES ANALYSIS; GASTROESOPHAGEAL REFLUX; GASTROINTESTINAL STROMAL TUMOR; HELICOBACTER INFECTION; HUMAN; IMMUNOHISTOCHEMISTRY; INTESTINE LYMPHOMA; NEUROENDOCRINE TUMOR; NUCLEAR MAGNETIC RESONANCE IMAGING; OCCULT BLOOD; POSITRON EMISSION TOMOGRAPHY; PROTEOMICS; RAMAN SPECTROMETRY; REVIEW; SIGMOIDOSCOPY; STOMACH ADENOCARCINOMA; STOMACH CANCER; STOMACH LYMPHOMA; TUMOR BIOPSY;

EID: 84921765874     PISSN: 20082258     EISSN: 20084234     Source Type: Journal    
DOI: None     Document Type: Review

References (152)

1. Dalilan S, Tavirani MR, Nabiuni M, Heidari-Keshel S, Azodi MZ, Zali H. Aqueous Extract of Lavender angustifolia Inhibits Lymphocytes Proliferation of Hodgkin's Lymphoma Patients. Iran J Cancer Prev 2013;6: 201-8.
2. Tavirani M, Zali H, Nasiri S, Shokrgozar M. Human calprotectin, a potent anticancer with minimal side effect. Iran J Cancer Prev 2009; 2:183-88.
3. Cho WC. Proteomics in translational cancer research: biomarker discovery for clinical applications. Expert Rev Proteomics 2014; 11:131-33.
4. Nia YZ, Majd HA, Azodi M, Khayyer N. Using partitioning and non-partitioning clustering algorithms for included proteins sequences in esophagus, stomach and colon cancer. Journal of Paramedical Sciences 2011; 2: 9-16.
5. Wouters MW, Gooiker GA, van Sandick JW, Tollenaar RA. The volume-outcome relation in the surgical treatment of esophageal cancer. Cancer 2012;118:1754-63.
6. Sgourakis G, Gockel I, Karaliotas C, Moehler M, Schimanski CC, Schmidberger H, et al. Survival after chemotherapy and/or radiotherapy versus selfexpanding metal stent insertion in the setting of inoperable esophageal cancer: a case-control study. BMC Cancer 2012; 12:70.
7. Polanski M, Anderson NL. A list of candidate cancer biomarkers for targeted proteomics. Biomark Insights 2007; 1:1-48.
8. Wang Q, Chaerkady R, Wu J, Hwang HJ, Papadopoulos N, Kopelovich L, et al. Mutant proteins as cancer-specific biomarkers. PNAS. 2011; 108:2444-49.
9. Nafar M, Kalantari S, Samavat S, Rezaei-Tavirani M, Rutishuser D, Zubarev RA. The Novel Diagnostic Biomarkers for Focal Segmental Glomerulosclerosis. ISRN nephrology. PNAS [In press].
10. Kalantari S, Rutishauser D, Samavat S, Nafar M, Mahmudieh L, Rezaei-Tavirani M, et al. Urinary Prognostic Biomarkers and Classification of IgA Nephropathy by High Resolution Mass Spectrometry Coupled with Liquid Chromatography. PloSone 2013;8:808-30.
11. Shi J LJ, Liao L, Guo Y, Wang H, Hu W, Hu T. Identification of candidate serum biomarkers for small cell lung cancer by proteomics analysis. Minerva Med 2014; 105:37-47.
12. Ludwig JA, Weinstein JN. Biomarkers in cancer staging, prognosis and treatment selection. Nat Rev Cancer 2005;5:845-56.
13. Pepe MS, Etzioni R, Feng Z, Potter JD, Thompson ML, Thornquist M, et al. Phases of biomarker development for early detection of cancer. JNCI 2001;93:1054-61.
14. Duffy M, Lamerz R, Haglund C, Nicolini A, Kalousova M, Holubec L, et al. Tumor markers in colorectal cancer, gastric cancer and gastrointestinal stromal cancers: European group on tumor markers 2014 guidelines update. Int J Cancer 2014; 134:2513-22.
15. Pooladi M, Rezaei-Tavirani M, Hashemi M, Hesami-Tackallou S, Khaghani-Razi-Abad S, Moradi A, et al. The Study of "Dihydropyrimidinase Related Proteins (DRPs)" Expression Changes Influence in Malignant Astrocytoma Brain Tumor. Iran J Cancer Prev 2014; 7:130-33.
16. Srinivas PR, Verma M, Zhao Y, Srivastava S. Proteomics for cancer biomarker discovery. Clin chem. 2002; 48:1160-69.
17. Sawyers CL. The cancer biomarker problem. Nature 2008;452:548-52.
18. Rusling JF, Kumar CV, Gutkind JS, Patel V. Measurement of biomarker proteins for point-of-care early detection and monitoring of cancer. Analyst 2010;135:2496-11.
19. Simpson RJ, Dorow DS. Cancer proteomics: from signaling networks to tumor markers. Trends Biochem Sci. 2001;19:40-48.
20. Ryu J-W, Kim H-J, Lee Y-S, Myong N-H, Hwang C-H, Lee G-S, et al. The proteomics approach to find biomarkers in gastric cancer. J Korean Med Sci. 2003;18:505.
21. Alaiya AA, Franzén B, Auer G, Linder S. Cancer proteomics: from identification of novel markers to creation of artifical learning models for tumor classification. Electrophoresis 2000;21:1210-17.
22. Rai AJ, Chan DW. Cancer proteomics: serum diagnostics for tumor marker discovery. Ann N Y Acad Sci 2004;1022:286-94.
23. Firpo MA, Boucher KM, Mulvihill SJ. Prospects for developing an accurate diagnostic biomarker panel for low prevalence cancers. Theor Biol Med Model 2014;11:34.
24. Chung L, Moore K, Phillips L, Boyle FM, Marsh DJ, Baxter RC. Novel serum protein biomarker panel revealed by mass spectrometry and its prognostic value in breast cancer. Breast Cancer Res Treat 2014;16:63.
25. Wulfkuhle JD, Liotta LA, Petricoin EF. Proteomic applications for the early detection of cancer. Nat Rev Cancer 2003; 3:267-75.
26. Zamanian-Azodi M, Vafaee R, Azodi T, Omidi R, Gilanchi S, Azizi-Jalilian F, et al. Molecular approaches in obesity studies. Gastroenterol Hepatol Bed Bench 2013;6:S23-31.
27. Zamanian-Azodi M, Rezaei-Tavirani M, Mortazavian A, Vafaee R, Rezaei-Tavirani M, Zali H, et al. Application of Proteomics in Cancer Study. American Journal of Cancer Science 2013;2:116-34.
28. Jafari M, Mirzaie M, Sadeghi M, Marashi S-A, Rezaei-Tavirani M. Exploring biological processes involved in embryonic stem cell differentiation by analyzing proteomic data. Biochim Biophys Acta 2013;1834:1063-69.
29. Kusiak RA, Ritchie AC, Springer J, Muller J. Mortality from stomach cancer in Ontario miners. Br J Ind Med 1993; 50:117-26.
30. Ricci-Vitiani L, Lombardi DG, Pilozzi E, Biffoni M, Todaro M, Peschle C, et al. Identification and expansion of human colon-cancer-initiating cells. Nature 2007; 445:111-15.
31. Zali H, Ahmadi G, Bakhshandeh R, Rezaei-Tavirani M. Proteomic analysis of gene expression during human esophagus cancer. Journal of Paramedical Sciences 2011; 2: 37-44.
32. Enzinger PC, Mayer RJ. Esophageal cancer. N Engl J Med 2003; 349:2241-52.
33. Agrawal N, Jiao Y, Bettegowda C, Hutfless SM, Wang Y, David S, et al. Comparative Genomic Analysis of Esophageal Adenocarcinoma and Squamous Cell Carcinoma. Cancer Discov 2012;2:899-905.
34. Shakhatreh MH, Duan Z, Avila N, Naik AD, Kramer JR, Hinojosa-Lindsey M, et al. Risk of upper gastrointestinal cancers in patients with gastroesophageal reflux disease following a negative screening endoscopy. Clin Gastroenterol Hepatol [In press].
35. Yoon HH, Shi Q, Sukov WR, Wiktor AE, Khan M, Sattler CA, et al. Association of HER2/ErbB2 expression and gene amplification with pathologic features and prognosis in esophageal adenocarcinomas. Clin Cancer Res 2012;18:546-54.
36. Madhusudhan C, Saluja SS, Pal S, Ahuja V, Saran P, Dash NR, et al. Palliative stenting for relief of dysphagia in patients with inoperable esophageal cancer: impact on quality of life. Dis Esophagus 2009;22:331-36.
37. Daly JM, Fry WA, Little AG, Winchester DP, McKee RF, Stewart AK, et al. Esophageal cancer: results of an American College of Surgeons patient care evaluation study. JCPSP 2000;190:562-72.
38. Layke JC, Lopez PP. Esophageal cancer: a review and update. AmFam Physician 2006;73:2187-94.
39. Mao W-M, Zheng W-H, Ling Z-Q. Epidemiologic risk factors for esophageal cancer development. Asian Pac J Cancer Prev 2011; 12:2461-66.
40. Oze I, Matsuo K, Wakai K, Nagata C, Mizoue T, Tanaka K, et al. Alcohol drinking and esophageal cancer risk: an evaluation based on a systematic review of epidemiologic evidence among the Japanese population. J ClinOncol Res 2011;41:677-92.
41. Salehi M, Moradi-Lakeh M, Salehi MH, Nojomi M, Kolahdooz F. Meat, fish, and esophageal cancer risk: a systematic review and dose-response meta-analysis. Nutr Rev 2013; 71:257-67.
42. Shaheen N, Ransohoff DF. Gastroesophageal reflux, Barrett esophagus, and esophageal cancer: scientific review. JAMA 2002;287:1972-81.
43. Cerfolio RJ, Bryant AS, Ohja B, Bartolucci AA, Eloubeidi MA. The accuracy of endoscopic ultrasonography with fine-needle aspiration, integrated positron emission tomography with computed tomography, and computed tomography in restaging patients with esophageal cancer after neoadjuvantchemoradiotherapy. J Thorac Cardiovasc Surg 2005;129:1232-41.
44. Jäckle S, Gladkova N, Feldchtein F, Terentieva A, Brand B, Gelikonov G, et al. In vivo endoscopic optical coherence tomography of esophagitis, Barrett's esophagus, and adenocarcinoma of the esophagus. Endoscopy 2000;32:750-55.
45. Komukai S, Nishimaki T, Watanabe H, Ajioka Y, Suzuki T, Hatakeyama K. Significance of immunohistochemically demonstrated micrometastases to lymph nodes in esophageal cancer with histologically negative nodes. Surgery 2000;127:40-46.
46. Wu S, Chen M, Wei L, Chen Z. Embedded Cervical Esophagogastrostomy: A Simple and Convenient Method Using a Circular Stapler After Esophagectomy for Esophageal Carcinomas. Ann Surg Oncol 2013;20:2984-90.
47. Smolinski KN, Abraham JM, Souza RF, Yin J, Wang S, Xu Y, et al. Activation of the Esophagin Promoter during Esophageal Epithelial Cell Differentiation. Genomics 2002;79:875-80.
48. Hasan R, Sharma R, Saraya A, Chattopadhyay TK, DattaGupta S, Walfish PG, et al. Mitogen activated protein kinase kinasekinase 3 (MAP3K3/MEKK3) overexpression is an early event in esophageal tumorigenesis and is a predictor of poor disease prognosis. BMC Cancer 2014; 14:2.
49. Ogawa R, Ishiguro H, Kuwabara Y, Kimura M, Mitsui A, Katada T, et al. Expression profiling of micro-RNAs in human esophageal squamous cell carcinoma using RT-PCR. Med Mol Morphol 2009;42:102-109.
50. Shi Y. Histone lysine demethylases: emerging roles in development, physiology and disease. Nature Rev Genet 2007; 8:829-33.
51. Kano Y, Konno M, Ohta K, Haraguchi N, Nishikawa S, Kagawa Y, et al. Jumonji/Arid1b (Jarid1b) protein modulates human esophageal cancer cell growth. Mol Clin Oncol 2013; 1:753-57.
52. Matias NMR. Exploring the role of the Jumonji/ARID1 family of proteins during embryonic stem cell differentiation and X-chromosome inactivation 2010;1:753-57.
53. Kano Y, Konno M, Kawamoto K, Tamari K, Hayashi K, Fukusumi T, et al. Novel drug discovery system for cancer stem cells in human squamous cell carcinoma of the esophagus. Oncol Rep. 2014;31:1133-38.
54. Roesch AO, Herlyn M. Compositions containing JARID1B inhibitors and methods for treating cancer. Available from: http://www.google.com/patents/CA2770307A1?cl=en
55. Nakamura Y, Hamamoto R, Tsunoda T. Jarid1b for target gene of cancer therapy and diagnosis. Available from: http://www.google.com/patents/EP2398901A1?cl=en
56. Jiang S, Li Y, Zhu YH, Wu XQ, Tang J, Li Z, et al. Intensive expression of UNC-51-like kinase 1 is a novel biomarker of poor prognosis in patients with esophageal squamous cell carcinoma. Cancer Sci 2011;102:1568-75.
57. Ogura K-i, Okada T, Mitani S, Gengyo-Ando K, Baillie DL, Kohara Y, et al. Protein phosphatase 2A cooperates with the autophagy-related kinase UNC-51 to regulate axon guidance in Caenorhabditiselegans. Development 2010;137:1657-67.
58. Jiang L, Duan B-S, Huang J-X, Jiao X, Zhu X-W, Sheng H-H, et al. Association of the expression of unc-51-Like kinase 1 with lymph node metastasis and survival in patients with esophageal squamous cell carcinoma. Int J Clin Exp Med 2014;7:1349.
59. Zali H, Rezaei-Tavirani M, Vafaee R, Rezaei-Tavirani M. Gastric cardia adenocarcinoma pathway analysis. Gastroenterol Hepatol Bed Bench. 2013;6: S11-18.
60. Fock KM. Review article: the epidemiology and prevention of gastric cancer. Aliment Pharmacol Ther 2014;40:250-60.
61. Khatib H, Rezaei-Tavirani M, Keshel SH, Azodi MZ, Omidi R, Biglarian M, et al. Flow cytometry analysis of Rosa Damascena effects on gastric cancer cell line (MKN45). Iran J Cancer Prev 2013;6:30-36.
62. Shokrgozar M, Zali H, RezaeiTavirani M. Evaluation of proliferation inhibition effect of human calprotectin on human gastric cancer cell line (AGS) in vitro. Yakhteh 2007; 4:254-68.
63. Zali H, Zamanian-Azodi M, Shokrgozar MA, Rezaei-Tavirani M. Cytotoxic effects of human calprotectin on gastric cancer cell line is attenuated by etoposide. Gastroenterol Hepatol Bed Bench 2012;5:132-38.
64. Liu W, Yang Q, Liu B, Zhu Z. Serum proteomics for gastric cancer. Clinica Chimica Acta 2014;431:179-84.
65. Hendricks J. Malignant tumors of the stomach. Surgclin North Am 1986;66:683-93.
66. Okines A, Verheij M, Allum W, Cunningham D, Cervantes A. Gastric cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2010;21:v50-v54.
67. He Q-Y, Cheung YH, Leung SY, Yuen ST, Chu KM, Chiu J-F. Diverse proteomic alterations in gastric adenocarcinoma. Proteomics 2004;4:3276-87.
68. Ghimire P, Wu G-Y, Zhu L. Primary gastrointestinal lymphoma. World J Gastroenterol 2011;17:697-707.
69. Goto R, Arai K, Kitada H, Ogoshi K, Hamashima C. Labor Resource Use for Endoscopic Gastric Cancer Screening in Japanese Primary Care Settings: A Work Sampling Study. PloSone 2014;9:1-6.
70. Hisamichi S. Screening for gastric cancer. World J Surg 1989;13:31-37.
71. Stell D, Carter C, Stewart I, Anderson J. Prospective comparison of laparoscopy, ultrasonography and computed tomography in the staging of gastric cancer. Br J Surg 1996;83:1260-62.
72. Oien KA, McGregor F, Butler S, Ferrier RK, Downie I, Bryce S, et al. Gastrokine 1 is abundantly and specifically expressed in superficial gastric epithelium, down-regulated in gastric carcinoma, and shows high evolutionary conservation. J Pathol 2004;203:789-97.
73. Yoon JH, Song JH, Zhang C, Jin M, Kang YH, Nam SW, et al. Inactivation of the Gastrokine 1 gene in gastric adenomas and carcinomas. J Pathol 2011;223:618-25.
74. Wu J-Y, Cheng C-C, Wang J-Y, Wu D-C, Hsieh JS, Lee S-C, et al. Discovery of tumor markers for gastric cancer by proteomics. PloSone. 2014;9:e84158.
75. Yan GR, Xu SH, Tan ZL, Yin XF, He QY. Proteomics characterization of gastrokine 1-induced growth inhibition of gastric cancer cells. Proteomics. 2011;11:3657-64.
76. He QY, Cheung YH, Leung SY, Yuen ST, Chu KM, Chiu JF. Diverse proteomic alterations in gastric adenocarcinoma. Proteomics 2004;4:3276-87.
77. Baus-Loncar M, Lubka M, Pusch CM, Otto WR, Poulsom R, Blin N. Cytokine regulation of the trefoil factor family binding protein GKN2 (GDDR/TFIZ1/blottin) in human gastrointestinal epithelial cells. Cell Physiol Biochem 2007;20:193-204.
78. Menheniott TR, Kurklu B, Giraud AS. Gastrokines: stomach-specific proteins with putative homeostatic and tumor suppressor roles. Am J PhysiolGastrointest Liver Physiol 2013;304:109-21.
79. Rippa E, La Monica G, Allocca R, Romano MF, De Palma M, Arcari P. Overexpression of gastrokine 1 in gastric cancer cells induces Fas-mediated apoptosis. J Cell Physiol 2011; 226:2571-8.
80. Martin G, Wex T, Treiber G, Malfertheiner P, Nardone G. Low-dose aspirin reduces the gene expression of gastrokine-1 in the antral mucosa of healthy subjects. Aliment pharmacol Ther 2008;28:782-88.
81. Cui J, Chen Y, Chou W-C, Sun L, Chen L, Suo J, et al. An integrated transcriptomic and computational analysis for biomarker identification in gastric cancer. Nucleic Acids Res 2011; 39:1197-207.
82. Abnet CC. Current and ongoing research projects related to gastric cancer prevention: perspective of the United States National Cancer Institute. Helicobacter pylori eradication as strategy for preventing gastric cancer. Lyon, France: International Agency for Research on Cancer; 2014. P.136.
83. Melle C, Ernst G, Schimmel B, Bleul A, Kaufmann R, Hommann M, et al. Characterization of pepsinogen C as a potential biomarker for gastric cancer using a histo-proteomic approach. Journal Proteome Rev 2005;4:1799-804.
84. Dame JB, Reddy GR, Yowell CA, Dunn BM, Kay J, Berry C. Sequence, expression and modeled structure of an aspartic proteinase from the human malaria parasitePlasmodium falciparum. Mol Biochem Parasit 1994;64:177-90.
85. Li H-m, Ning P-f, Yuan Y. Contrastive study of the tissue expression and serum concentration of pepsinogen C in gastric mucosa diseases. Chines J Cancer Res 2006;18:8-11.
86. Chen L, Su L, Li J, Zheng Y, Yu B, Yu Y, et al. Hypermethylated FAM5C and MYLK in serum as diagnosis and pre-warning markers for gastric cancer. Dis Markers 2012;32(3):195-202.
87. Hao Y, Yu Y, Wang L, Yan M, Ji J, Qu Y, et al. IPO-38 is identified as a novel serum biomarker of gastric cancer based on clinical proteomics technology. J Proteome Res 2008; 7:3668-77.
88. Lin L-L, Huang H-C, Juan H-F. Discovery of biomarkers for gastric cancer: a proteomics approach. J Proteomics 2012;75:3081-97.
89. Jasperson KW, Tuohy TM, Neklason DW, Burt RW. Hereditary and familial colon cancer. Gastroenterology 2010;138:2044-58.
90. Rezaie-Tavirani M, Fayazfar S, Heydari-Keshel S, Rezaee MB, Zamanian-Azodi M, Rezaei-Tavirani M, et al. Effect of essential oil of Rosa Damascena on human colon cancer cell line SW742. Gastroenterol Hepatol Bed Bench 2013; 6:25-31.
91. Safaei A, Sobhi S, Rezaei-Tavirani M, Zali MR. Genomic and epigenetic instability in colorectal cancer. Iran J Cancer Prev 2013; 6:54-63.
92. Yu J-K, Chen Y-D, Zheng S. An integrated approach to the detection of colorectal cancer utilizing proteomics and bioinformatics. World J Gastroenterol 2004;10:3127-31.
93. Snover DC. Update on the serrated pathway to colorectal carcinoma. Hum Pathol 2011; 42:1-10.
94. Fan C-W, Changchien CR, Wang J-Y, Chen J-S, Hsu K-C, Tang R, et al. Primary colorectal lymphoma. Dis Colon Rectum 2000;43:1277-82.
95. Comer TP, Beahrs OH, Dockerty MB. Primary squamous cell carcinoma and adenoacanthoma of the colon. Cancer 1971;28:1111-17.
96. Miettinen M, Sarlomo-Rikala M, Sobin LH, Lasota J. Gastrointestinal stromal tumors and leiomyosarcomas in the colon: a clinicopathologic, immunohistochemical, and molecular genetic study of 44 cases. Am Surg Pathol 2000;24:1339-52.
97. Stinner B, Kisker O, Zielke A, Rothmund M. Surgical management for carcinoid tumors of small bowel, appendix, colon, and rectum. World J Surg 1996;20:183-88.
98. Astin M, Griffin T, Neal RD, Rose P, Hamilton W. The diagnostic value of symptoms for colorectal cancer in primary care: a systematic review. Br J Gen Pract 2011;61:231-43.
99. Nishihara R, Lochhead P, Kuchiba A, et al. ASpirin use and risk of colorectal cancer according to braf mutation status. JAMA 2013;309:2563-71.
100. Thun MJ, Jacobs EJ, Patrono C. The role of aspirin in cancer prevention. Nat Rev Clin Oncol 2012; 9:259-67.
101. Trock B, Lanza E, Greenwald P. Dietary fiber, vegetables, and colon cancer: Critical review and metaanalyses of the epidemiologic evidence. J Natl Cancer Inst 1990; 82:650-61.
102. Xue G, Wang X, Yang Y, Liu D, Cheng Y, Zhou J, et al. Colon Cancer-Specific Antigen-2 May Be Used as a Detecting and Prognostic Marker in Colorectal Cancer: A Preliminary Observation. PloSone 2014;9:e94252.
103. Young PE, Womeldorph CM. Colonoscopy for colorectal cancer screening. J Cancer 2013;4:217.
104. Shen H, Huang J, Pei H, Zeng S, Tao Y, Shen L, et al. Comparative proteomic study for profiling differentially expressed proteins between Chinese left-and right-sided colon cancers. Cancer Sci 2013;104:135-41.
105. Rho J-h, Qin S, Wang JY, Roehrl MH. Proteomic expression analysis of surgical human colorectal cancer tissues: up-regulation of PSB7, PRDX1, and SRP9 and hypoxic adaptation in cancer. J Proteome Res 2008;7:2959-72.
106. Coux O, Tanaka K, Goldberg AL. Structure and functions of the 20S and 26S proteasomes. Ann Rev Biochem 1996;65:801-47.
107. Knychalski B, Lukienczuk T. The evaluation of diagnostic value of the tumor markers: CCSA-2 and CEA in colorectal cancer. Pol J Surg 2012;84:86-92.
108. Leman ES, Schoen RE, Magheli A, Sokoll LJ, Chan DW, Getzenberg RH. Evaluation of colon cancer-specific antigen 2 as a potential serum marker for colorectal cancer. Clin. Cancer Res 2008;14:1349-54.
109. Leman ES, Schoen RE, Weissfeld JL, Cannon GW, Sokoll LJ, Chan DW, et al. Initial analyses of colon cancer-specific antigen (CCSA)-3 and CCSA-4 as colorectal cancer-associated serum markers. Cancer Res 2007;67:5600-605.
110. Chen X, Ba Y, Ma L, Cai X, Yin Y, Wang K, et al. Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res 2008;18:997-1006.
111. Walgenbach-Brunagel G, Burger B, Leman ES, Walgenbach KJ, Tolba R, Heukamp L, et al. The use of a colon cancer associated nuclear antigen CCSA-2 for the blood based detection of colon cancer. J Cell Biochem 2008;104:286-94.
112. Gupta AK, Brenner DE, Turgeon DK. Early Detection of Colon Cancer. Mol Diag Ther 2008;12:77-85.
113. Rezaei TM, Zali H, Rastegar JF, Heydari H, Hosseinzadeh SB, Daneshi MF, et al. Paper: Introducing Aldolase C as A Differentional Biomarker: A Proteomics Approach. Mol Diag Ther 2008;12:77-85.
114. Hasanzadeh H, Rezaie-Tavirani M, Seyyedi SS, Zali H, Keshel SH, Jadidi M, et al. Effect of ELF-EMF Exposure on Human Neuroblastoma Cell Line: a Proteomics Analysis. Iran J Cancer Prev 2014;7:22-27.
115. De Vita F, Di Martino N, Fabozzi A, Laterza MM, Ventriglia J, Savastano B, et al. Clinical management of advanced gastric cancer: The role of new molecular drugs. World J Gastroenterol 2014;20:14537-58.
116. Babashah S, Sadeghizadeh M, Tavirani MR, Farivar S, Soleimani M. Aberrant microRNA expression and its implications in the pathogenesis of leukemias. Cell Oncol 2012;35:317-34.
117. Partin AW, Catalona WJ, Southwick PC, Subong EN, Gasior GH, Chan DW. Analysis of percent free prostate-specific antigen (PSA) for prostate cancer detection: influence of total PSA, prostate volume, and age. Urology 1996;48:55-61.
118. Zamanian-Azodi M, Rezaie-Tavirani M, Heydari-Kashal S, Kalantari S, Dailian S, Zali H. Proteomics analysis of MKN45 cell line before and after treatment with Lavender aqueous extract. Gastroenterol Hepatol Bed Bench 2012;5 :35-42.
119. Maurya P, Meleady P, Dowling P, Clynes M. Proteomic approaches for serum biomarker discovery in cancer. Anticancer Res 2007;27:1247-55.
120. Urakami S, Shiina H, Enokida H, Kawakami T, Kawamoto K, Hirata H, et al. Combination analysis of hypermethylatedWnt-antagonist family genes as a novel epigenetic biomarker panel for bladder cancer detection. Clin Cancer Res 2006;12:2109-16.
121. Ring BZ, Seitz RS, Beck R, Shasteen WJ, Tarr SM, Cheang MC, et al. Novel prognostic immunohistochemical biomarker panel for estrogen receptor-positive breast cancer. J Clin Oncol 2006;24:3039-47.
122. Nie S, Lo A, Wu J, Zhu J, Tan Z, Simeone DM, et al. Glycoprotein Biomarker Panel for Pancreatic Cancer Discovered by Quantitative Proteomics Analysis. J proteome Res 2014;13:1873-84.
123. Kumar A, Chatopadhyay T, Raziuddin M, Ralhan R. Discovery of deregulation of zinc homeostasis and its associated genes in esophageal squamous cell carcinoma using cDNA microarray. Int J Cancer 2007;120:230-42.
124. Zhang HA. MAP3K3/MEKK3 Is an amplified and overexpressed novel oncogene in breast cancer. J Clin Exp Pathol 2012;2:25-32.
125. Burchard J, Zhang C, Liu AM, Poon RT, Lee NP, Wong KF, et al. MicroRNA-122 as a regulator of mitochondrial metabolic gene network in hepatocellular carcinoma. Mol Syst Biol 2010; 6:402.
126. Xiang Y, Zhu Z, Han G, Ye X, Xu B, Peng Z, et al. JARID1B is a histone H3 lysine 4 demethylase upregulated in prostate cancer. ProcNatlAcadSci U S A. 2007;104:19226-31.
127. Mitra D, Das PM, Huynh FC, Jones FE. Jumonji/ARID1 B (JARID1B) protein promotes breast tumor cell cycle progression through epigenetic repression of microRNA let-7e. J Biol Chem. 2011;286:40531-35.
128. Kuzbicki L, Lange D, Straczynska-Niemiec A, Chwirot BW. JARID1B expression in human melanoma and benign melanocytic skin lesions. Melanoma Res 2013;23:8-12.
129. Dai J, Zhang N, Wang J, Chen M, Chen J. Gastrokine-2 is downregulated in gastric cancer and its restoration suppresses gastric tumorigenesis and cancer metastasis. Tumor Biol 2014;35:4199-207.
130. Lu F, Tempera I, Lee HT, DeWispelaere K, Lieberman PM. EBNA1 binding and epigenetic regulation of gastrokine tumor suppressor genes in gastric carcinoma cells. Virol J 2014;11:12.
131. Menheniott TR, Peterson AJ, O'Connor L, Lee KS, Kalantzis A, Kondova I, et al. A Novel Gastrokine, Gkn3, Marks Gastric Atrophy and Shows Evidence of Adaptive Gene Loss in Humans. Gastroenterology 2010;138:1823-35.
132. Altieri F, Stadio D, Stella C, Severino V, Sandomenico A, Minopoli G, et al. Anti-amyloidogenic property of human gastrokine 1. Biochimie 2014;106:91-100.
133. Nardone G, Martin G, Rocco A, Rippa E, La Monica G, Caruso F, et al. Molecular expression of Gastrokine 1 in normal mucosa and in Helicobacter pylori-related preneoplastic and neoplastic gastric lesions. Cancer Biol Ther 2008;7:1890-95.
134. Ning P-F, Liu H-J, Yuan Y. Dynamic expression of pepsinogen C in gastric cancer, precancerous lesions and Helicobacter pylori associated gastric diseases. World J Gastroenterol 2005;11:2545-48.
135. Balbín M, López-Otín C. Hormonal Regulation of the Human Pepsinogen C Gene in Breast Cancer Cells Identification of Cis-Acting Element Mediating Its Induction by Androgens, Glucocorticoids, and Progestrone. J Biol Chem 1996;271:15175-81.
136. Thosaporn W, Iamaroon A, Pongsiriwet S, Ng K. A comparative study of epithelial cell proliferation between the odontogenickeratocyst, orthokeratinizedodontogenic cyst, dentigerous cyst, and ameloblastoma. Oral Dis 2004;10:22-6.
137. Amaral FR, Mateus GCP, Bonisson LA, Andrade BABd, Mesquita RA, Horta MCR, et al. Cell proliferation and apoptosis in ameloblastomas and keratocysticodontogenic tumors. Braz Dent J. 2012;23:91-96.
138. Violette S, Festor E, Pandrea-Vasile I, Mitchell V, Adida C, Dussaulx E, et al. Reg IV, a new member of the regenerating gene family, is overexpressed in colorectal carcinomas. Intl J Cancer. 2003;103:185-93.
139. Mitani Y, Oue N, Matsumura S, Yoshida K, Noguchi T, Ito M, et al. Reg IV is a serum biomarker for gastric cancer patients and predicts response to 5-fluorouracil-based chemotherapy. Oncogene 2007;26:4383-93.
140. Michaeli A, Finci-Yeheskel Z, Dishon S, Linke RP, Levin M, Urieli-Shoval S. Serum amyloid A enhances plasminogen activation: implication for a role in colon cancer. BiochemBiophys Res Commun 2008;368:368-73.
141. Chan D-C, Chen C-J, Chu H-C, Chang W-K, Yu JC, Chen Y-J, et al. Evaluation of serum amyloid A as a biomarker for gastric cancer. Ann Surg Oncol 2007;14:84-93.
142. Nakajima TE, Yamada Y, Hamano T, Furuta K, Matsuda T, Fujita S, et al. Adipocytokines as new promising markers of colorectal tumors: adiponectin for colorectal adenoma, and resistin and visfatin for colorectal cancer. Cancer Sci 2010;101:1286-91.
143. Nakajima TE, Yamada Y, Hamano T, Furuta K, Gotoda T, Katai H, et al. Adipocytokine levels in gastric cancer patients: resistin and visfatin as biomarkers of gastric cancer. Am J Gastroenterol 2009;44:685-90.
144. Kawamori T, Kaneshiro T, Okumura M, Maalouf S, Uflacker A, Bielawski J, et al. Role for sphingosinekinase 1 in colon carcinogenesis. FASEB J 2009; 23:405-14.
145. Li W, Yu C-P, Xia J-t, Zhang L, Weng G-X, Zheng H-q, et al. Sphingosine kinase 1 is associated with gastric cancer progression and poor survival of patients. Clin Cancer Res. 2009;15(4):1393-9.
146. Yeo M, Park HJ, Kim DK, Kim YB, Cheong JY, Lee KJ, et al. Loss of SM22 is a characteristic signature of colon carcinogenesis and its restoration suppresses colon tumorigenicity in vivo and in vitro. Cancer 2010;116:2581-89.
147. Li N, Zhang J, Liang Y, Shao J, Peng F, Sun M, et al. A controversial tumor marker: is SM22 a proper biomarker for gastric cancer cells? J Proteome Res 2007; 6:3304-12.
148. Tänzer M, Liebl M, Quante M. Molecular biomarkers in esophageal, gastric, and colorectal adenocarcinoma. Aliment Pharmacol Ther 2013;140:133-47.
149. de Wit M, Fijneman RJA, Verheul HMW, Meijer GA, Jimenez CR. Proteomics in colorectal cancer translational research: Biomarker discovery for clinical applications. Clin Biochem 2013; 46:466-79.
150. Kalantari S, Nafar M, Samavat S, Rezaei-Tavirani M, Rutishauser D, Zubarev R. Urinary Prognostic Biomarkers in Patients With Focal Segmental Glomerulosclerosis. Nephrourol Mon 2014; 6:1-4.
151. Pooladi M, Rezaei-Tavirani M, Hashemi M, Hesami-Tackallou S, Khaghani-Razi-Abad S, Moradi A, et al. Cluster and Principal Component Analysis of Human GlioblastomaMultiforme (GBM) Tumor Proteome. Iran J Cancer Prev 2014; 7:87-95.
152. Kalantari S, Nafar M, Rutishauser D, Samavat S, Rezaei-Tavirani M, Yang H, et al. Predictive urinary biomarkers for steroid-resistant and steroid-sensitive focal segmental glomerulosclerosis using high resolution mass spectrometry and multivariate statistical analysis. BMC Nephrology 2014;15:141.